---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-350425"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2026-08-14T11:50:16+00:00"
generated_at: "2026-08-14T11:55:25.181918+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TuHURA Q2 2026: cash $1.0M, R&D up to $6.6M, $50M credit facility extends runway to 2028

## Summary
- Cash and equivalents $1.0M at June 30, 2026; $5.7M drawn on $50M Parkview credit facility to date.
- R&D expenses $6.6M in Q2 2026 vs $4.9M in Q2 2025; G&A $2.1M vs $1.9M.
- Net operating cash outflow -$13.0M for H1 2026 vs -$10.9M in H1 2025; financing inflows $10.6M.
- Filed IND for TBS-2025 VISTA antibody in AML; expect Phase 1b/2 initiation 2H 2026 and orphan drug designations.
- $50M credit facility from largest shareholder at 12% interest, maturity 2031, extends cash runway into 2028.

## SEC filing metadata
- accession: 0001193125-26-350425
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2026-08-14T11:50:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/0001193125-26-350425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/hura-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-350425
- JSON: https://secwatch.observer/filing/0001193125-26-350425.json
- Plain text: https://secwatch.observer/filing/0001193125-26-350425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.